Table 2.
Relationship between the clinicopathological characteristics of the investigated breast tumors and the kinetic parameters of the performed dynamic PET examinations
| Feature (No. of tumors) | K1 mean |
k2 mean |
k3 mean |
Ki mean |
MRFDG mean |
|---|---|---|---|---|---|
| Clinical T stage | |||||
| T1c (4) | 0.185 | 0.543 | 0.062 | 0.018 | 8.701 |
| T2 (26) | 0.375 | 1.095 | 0.099 | 0.036 | 17.531 |
| T3 (5) | 0.258 | 0.779 | 0.164 | 0.044 | 23.292 |
| p value | 0.3742 | 0.9003 | 0.2206 | 0.0834 | 0.0780 |
| Clinical N stage | |||||
| N0 (9) | 0.292 | 0.909 | 0.076 | 0.023 | 12.961 |
| N1–3 (26) | 0.352 | 1.014 | 0.114 | 0.039 | 18.862 |
| p value | 0.5459 | 0.2271 | 0.2575 | 0.0315 | 0.1046 |
| Histology * | |||||
| IBC-NST (30) | 0.337 | 1.004 | 0.101 | 0.034 | 16.951 |
| other (5) | 0.333 | 0.884 | 0.125 | 0.041 | 19.709 |
| Nuclear grade † | |||||
| 1 (2) | 0.149 | 0.427 | 0.049 | 0.015 | 6.148 |
| 2 (8) | 0.353 | 0.983 | 0.071 | 0.022 | 10.838 |
| 3 (19) | 0.371 | 1.157 | 0.129 | 0.042 | 21.875 |
| p value | 0.3075 | 0.3417 | 0.0246 | 0.0089 | 0.0076 |
| ER status | |||||
| positive (24) | 0.279 | 0.727 | 0.094 | 0.032 | 14.934 |
| negative (11) | 0.462 | 1.555 | 0.128 | 0.041 | 22.604 |
| p value | 0.4095 | 0.5872 | 0.0667 | 0.0300 | 0.0247 |
| PR status | |||||
| positive (22) | 0.277 | 0.735 | 0.088 | 0.029 | 13.775 |
| negative (13) | 0.436 | 1.414 | 0.132 | 0.044 | 23.386 |
| p value | 0.2035 | 0.5782 | 0.0344 | 0.0217 | 0.0132 |
| HER2 status | |||||
| positive (6) | 0.369 | 1.136 | 0.104 | 0.033 | 15.824 |
| negative (29) | 0.329 | 0.956 | 0.105 | 0.035 | 17.659 |
| p value | 0.5933 | 0.2184 | 0.4801 | 0.8814 | 0.9151 |
| Ki-67 LI | |||||
| low (8) | 0.269 | 0.802 | 0.062 | 0.021 | 9.931 |
| high (27) | 0.356 | 1.042 | 0.117 | 0.039 | 19.542 |
| p value | 0.8323 | 0.9843 | 0.0414 | 0.0193 | 0.0271 |
| Subtype | |||||
| Triple negative (8) | 0.456 | 1.602 | 0.134 | 0.043 | 23.844 |
| HR-/HER2+ (2) | 0.674 | 2.087 | 0.136 | 0.041 | 21.863 |
| HR+/HER2+ (4) | 0.217 | 0.661 | 0.088 | 0.029 | 12.804 |
| HR+/HER2- (21) | 0.281 | 0.710 | 0.093 | 0.032 | 15.303 |
| p value (all) | 0.1932 | 0.2396 | 0.1666 | 0.1865 | 0.1374 |
| p value (TNBC and HER2+ vs. all HR+) | 0.1514 | 0.2703 | 0.0310 | 0.0280 | 0.0186 |
| TIL‡ | |||||
| TIL ≤1% (8) | 0.225 | 0.483 | 0.089 | 0.033 | 15.346 |
| 1% < TIL <20% (12) | 0.347 | 1.023 | 0.109 | 0.036 | 18.807 |
| TIL ≥20% (3) | 0.742 | 2.916 | 0.095 | 0.032 | 16.048 |
| p value (all) | 0.4713 | 0.0940 | 0.2055 | 0.5849 | 0.4346 |
p values: in bold. Underlined: statistically significant difference
*Due to low case numbers and statistical power we did not perform a statistical comparison;
† Missing in case of 6 tumors; ‡ missing in case of 12 tumors
Abbreviations: IBC NST invasive breast carcinomas of no special type, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, Ki-67 LI Ki-67 labeling index, TNBC triple negative, HR−/ HER2+ hormone-receptor negative and HER2-positive, HR+/ HER2+ hormone-receptor positive and HER2-positive, HR+/ HER2+ hormone-receptor positive and HER2-negative, TIL tumor infiltrating lymphocytes